

# The effect of "CD11781/I, CD10394/101A and CD11406/B" in the transplant model of psoriasis.

Published: 29-08-2016

Last updated: 14-04-2024

The aim of the project is to study the effect of "CD11781/I, CD10394/101A and CD11406/B" on typical skin features of psoriasis. This information can establish the most effective compound, right formulation and dose for further clinical...

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Epidermal and dermal conditions
<b>Study type</b>	Observational invasive

## Summary

### ID

NL-OMON42829

### Source

ToetsingOnline

### Brief title

Transplant model of psoriasis

### Condition

- Epidermal and dermal conditions

### Synonym

psoriasis

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Derphartox

**Source(s) of monetary or material Support:** Farmaceutische industrie

## Intervention

**Keyword:** model, psoriasis, transplant

## Outcome measures

### Primary outcome

Effect on typical psoriasis skin features after treatment with "CD11781/I, CD10394/101A and CD11406/B".

### Secondary outcome

-

## Study description

### Background summary

Psoriasis is an autoimmune disease in which proinflammatory protein mediators, released by skin cells and infiltrating cells, cause an abnormal cell division and differentiation. It may be possible to treat psoriasis using drugs aimed at preventing the synthesis of such mediators.

### Study objective

The aim of the project is to study the effect of "CD11781/I, CD10394/101A and CD11406/B" on typical skin features of psoriasis. This information can establish the most effective compound, right formulation and dose for further clinical research.

### Study design

Lesional skin biopsies of 6 mm in diameter will be treated with "CD11781/I, CD10394/101A and CD11406/B" using the transplant model of psoriasis. By measuring the effect on typical psoriasis skin features, it is possible to establish the most effective compound, the right formulation and dose for further clinical research.

### Study burden and risks

The health risks associated with taking blood & skin biopsies are small. It is

possible to obtain a slight scar formation and/or discolouration at the site of the biopsy punch.

## Contacts

### Public

Derphartox

Wytemaweg 80  
Rotterdam 3015 CN  
NL

### Scientific

Derphartox

Wytemaweg 80  
Rotterdam 3015 CN  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)  
Elderly (65 years and older)

### Inclusion criteria

Patients with moderate to severe psoriasis

### Exclusion criteria

Volunteers undergoing UV/light therapy or taking systemic drugs such as cyclosporin A or methotrexate

Volunteers using local topical corticosteroids  
Volunteers developing psoriasis at wound sites (Köbner phenomenon)

## Study design

### Design

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Other

### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 03-10-2016

Enrollment: 14

Type: Actual

## Ethics review

Approved WMO

Date: 29-08-2016

Application type: First submission

Review commission: METC Leiden-Den Haag-Delft (Leiden)

metc-ldd@lumc.nl

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

**Other (possibly less up-to-date) registrations in this register**

No registrations found.

**In other registers**

Register	ID
CCMO	NL58081.098.16